3-[N,N-bis(2-methoxyethyl)aminosulfonyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[N,N-bis(2-methoxyethyl)aminosulfonyl]benzoic acid
• 英文别名: 3-[bis(2-methoxyethyl)sulfamoyl]benzoic acid
• 化学式: C₁₃H₁₉NO₆S
• mdl: MFCD05263669
• 分子量: 317.363
• InChiKey: SWDHUAAHZSDXPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-[N,N-bis(2-methoxyethyl)aminosulfonyl]benzoic acid 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 1.0h， 生成 3-[bis-(2-methoxy-ethyl)-sulfamoyl]-benzoyl chloride
  参考文献：
  名称：

  具有抗血小板活性的新型嘌呤

  摘要：

  四种嘌呤 - 2,6 - 二胺，4a, b, 5a, b，十九种 N-（嘌呤 - 2 - 基）苯甲酰胺 6a - q, 7b 和一种 N-（嘌呤 - 2 - 基） -2 - 呋喃甲酰胺 8首次制备并测试它们对血小板聚集的抑制作用。6a、b、h、m、o、p六种化合物在Born试验中抑制胶原诱导的血小板聚集，IC50值在3～10μmol/L之间。ADP、PAF和肾上腺素被用作特异性聚集诱导剂来检查抗聚集活性的机制。观察到惊人的纳米摩尔级活动模式，6m、7b、8 甚至亚纳摩尔范围（6b）。化合物6b以IC50 = 0.45 nM（6m：3.5 nM；8：30 nM）抑制ADP诱导的血小板聚集。化合物 7b 显示出对诱导剂肾上腺素的拮抗作用，IC 50 = 1.8 nM (6o: 20 nM; 8: 30 nM)。

  DOI：

  10.1002/ardp.200500189

文献信息

• DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME
  申请人：Del Mar Pharmaceuticals

  公开号：EP3217970A1

  公开（公告）日：2017-09-20
• USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20190015379A1

  公开（公告）日：2019-01-17

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
• US9487522B2
  申请人：——

  公开号：US9487522B2

  公开（公告）日：2016-11-08
• [EN] SSH-2 (SLINGSHOT-2) INHIBITORS AND METHODS FOR MAKING AND USING THEM<br/>[FR] INHIBITEURS DE SSH-2 (SLINGSHOT-2) ET PROCÉDÉS POUR LES PRÉPARER ET LES UTILISER
  申请人：UNIV CALIFORNIA

  公开号：WO2012129057A2

  公开（公告）日：2012-09-27

  In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease.
• [EN] DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL EN COMBINAISON AVEC DES RAYONS, POUR TRAITER LE CANCER DU POUMON NON À PETITES CELLULES ET LE GLIOBLASTOME MULTIFORME
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2016077264A1

  公开（公告）日：2016-05-19

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.